参考文献
[1]Mosselman S.Polman J，Dijkema R.ER-ß：identification and characterization of a novel human estrogen receptor.FEBSLett，1996，392(1)：49.
[2]Pace P，Taylor J，Suntharalingam S，et al.Human estrogen receptor-ßbinds DNA in a manner similar to and dimerizes with estrogen receptorα.J Biol Chem，1997，272(41)：25832.
[3]Cullen R，Maguire T M，McDermott E W，et al.Studies on oestrogen receptoralpha and-beta mRNA in breast cancer.Eur J Cancer，2001，37(9)：1118.
[4]Endoh H，Maruyama K，Masuhiro Y，et al.Purification and identification of p68 RNA hclicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha.Mol Cell Biol.1999，19：5363-5372.
[5]Oesterreich S，Zhang P，Guler R L，et al.Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulinlike growth factor-mediated signaling and growth.Canær Res，2001，61(15)：5771.
[6]Bartkova J，Lukas J，Muller H，et al.Cycline ddDl protein expression and function in human breast cancer.Int J Cancer，1995，57(3)：353.
[7]Mosselman S，Polman J，Dijkma R.ERß：identification and characterization of a novel human estrogen receptor.FEBS Lett，1996，392：49-53.
[8]美国临床肿瘤学会和美国病理学家学会.乳腺癌雌激素、孕激素受体免疫组化检测指南.中华乳腺病杂志(电子版本)，2011，5(3)：385.
[9]Jensen E V.Jordan V C.The estrogen receptor：a model for molccular medicine.Clin Cancer Res.2003，9：1980-1989.
[10]Horwitz K B.The central role of progesterone receptors and progestational agents in the management and treatment of breast cancer.Semin Oncol.1988，15：14-19.
[11]Meyer M R.Haa S E.Prossnitz E R.et al.Nongenomic regulation of-vascular cell function and growth by elrogen.Mol Cell Endoc rinol.2009，301：L9-16.
[12]Rosenfe ld M G，Glass C K.Coregulator codcs of transcriptional regulation by nuclear receptors.J Biol Chem.2001，276：36865-36868.
[13]Walter P，Green S，Greene G，et al.Cloning of the human estrogen receptor cDNA.Proc Nat l Acad Sci USA.1985，82：7889-7893.
[14]孙燕.乳腺癌化学治疗的临床应用现状//吴桓兴.肿瘤学进展——化学治疗.上海：科学技术出版社，1965.
[15]Jordan Vc.Gapslur S.Morrow M.Selective estrogen receptor modulation and reduction in risk of breast cancer，osteoporosis，and coronary heart disease.J Natl Cancer Inst.2001，93：1449-1457.
[16]Wang R A，Mazumdar A，Kurnar R，et al.p21ctivated kinase-1 phosphorylates and transactivates estrogen receptor-α and promotes hyperplasia in mammary epithelium.EMBO J.2002，21：5437-5447.
[17]Price RH Jr，Butler C A，Webb P，et al.A splice variant of estrogen receptor beta missing exol1 3 displays altered subnuclear localization and capacity for transcriptional activatianl.Endocrinolngy，2006，142(5)：2039-2049.
[18]Li SL.Peri-operative CU adjuvent chemotherapy in operable breast cancer(10-year result).第四届国际乳腺癌辅助治疗学术会议论文集.1992年，瑞士.
[19]Milla-Santos A，Milla L，Rallo L，et al.PhaseIII randomized trial of toremifene vs tamoxifen in hormono-dependant advanced breast cancer.Breast Cancer Res Treat，2001，65(2)：119.
[20]Forward D P，Cheung K L，Jackson L，et al.Clinical and endocrine data for goserelin plus anastrozole as second line endocrine therapy for premenopausal advanced breast cancer.Br Cancer.2004，9(3)：590-594.
[21]Rose C.A comparison of the efficacy of aromatase inhibitors in secondline treatment of metastatic breast cancerAmJ Clin Oncol.2003，26(4)：S9-S16.
[22]Bonneterre J，Thurlimann B，Robertson J F，et al.Anas trozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women：results of the Tamoxifen or Arimidex Randomized Group Efficacyand Tolerability study.Gin Oncol，2000，18：3748-3757.
[23]Boccardo F，Rubagotti A，Amoroso D，et al.Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients：Results of an ltalian cooperative study.Clin Oncol，2001，19(22)：4209-4215.
[24]Lonning P E，Bajetta E，Murray R，et al.Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitor：a phase II trial.Clin Oncol，2000，18(11)：2234-2244.
[25]Baum M，Budzar A U，Cuzick J.et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer：first results of the AfAC randomized trial.Lancet，2002，359：2131-2139.(https://www.daowen.com)
[26]Dixon J M，Anderson T J，Miller W R.Neoadjuvant endocrine therapy of breast cancer：a surgical perspective.Eur J Cancer，2002，38：2214-2221.
[27]Ellis M I，Andrew C，Baljit S，et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/ErbB-2 positive，estrogen receptor positive primary breast cancer evidence from a phase III randomized trial.Clin Oncol，2001，19：3808-3816.
[28]孙燕，周际昌，蒋秉东，等.三乙烯硫代磷酌胶(I摩替派)合并性激素治疗乳腺癌肺转移瘤30例报告中华内科杂志，1963，11：560.
[29]Baum M，Budzar A U，Cuzick J，et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer：first results of the AT AC randomized trial.Lancet.2002，359(9324)：2131.
[30]Klijn J G，Bal mey R W，Boccardo F，et al.Combined tamoxifen and luteinizing hormone releasing hormone(LHRH)agonist versus LHRH agonist alone in premenopausal advanced breast cancer：meta-analysis of four randomized trials.Clin Oncol.2001，19(2)：343-353.
[31]Labholtz J M，Buzdar A，Pollak M，et al.Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women：results of a North American multicenter randomized trial.Arimidex Study Group.Clin Oncol，2000，18：3758-3767.
[32]Clemons M，Coleman R E，Verma S.Aromatase inhibitors in the adjuvant setting：bringing the gold to a standard?Cancer Treat，Rev，2004，30(4)：325-332.
[33]Paridaens R，Dirix L，Lohrisch C，et al.Mature results of a randomized phaseII multicenter study of exemestane versus tamoxifen as firstline hormone therapy for postmenopausal women with metastatic breast cancer.Ann oncol.2003，14(9)：1391-1398.
[34]Lonning P E.Aromatase inhibitors in breast cancer.Endocr Relat Cancer.2004，11(2)：179-189.
[35]Eiermann W，Paepke S，Appfelstaedt J，et al.Preoperative treatment of postmenopausal breast cancer patients with letrozole：A randomized double-blind multicenter study.Ann Oncol.2001，12：1527-1532.
[36]Dixon J M，Love C D，Bellary C O，et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer.Breast Cam'er Res Treat，2001，66：191-199.
[37]马线，吴世凯，孟祥颖，等.孕激素类药物解救治疗芳香化酶抑制剂耐药的转移性乳腺癌的临床研究.中国肿瘤临床，2012，39(8)：443-446.
[38]Smith IE.Dowsett M.Aromatase inhibitors in breast cancer.N Engl NE d.2003，348：2431-2442.
[39]吴世凯，宋三泰.第三代芳香化酶抑制剂临床应用的常见不良反应.药物警戒，2006，3(2)：68-71.
[40]宋三泰，吴世凯.芳香化酶抑制剂治疗乳腺癌应该注意的几个问题.肿瘤研究与临床，2005，17(6)：36 1-363.
[41]Simpson D，Curran M P.Perry CM Letrozole：a review of its use in postmenopausal women with breast cancer.Drugs，2004，64(11)：1213-1230.
[42]Buzdar A，Douma J，Davidson N，et al.Phase Ill.mul ticenter，doubleblind.randomized study of letrozole.an aromatase inhibitor，for advanced breast cancer versus megestrol acetate J Clin Oncol，2001，19(14)：3357-3366.
[43]宋三泰，汤仲明.乳腺癌内分泌治疗的策略和模式.实用肿瘤杂志，1996，10(2)：8-11.
[44]宋三泰，江泽飞.乳腺癌内分泌治疗的现状及应用策略.中华肿瘤杂志，1999，21(4)：312-313.
[45]宋三泰，江泽飞.乳腺癌内科治疗的基本思路.中国实用外科杂志，2003，23(10)：580-582.
[46]张天锡，汪道新，史玉泉.脑下垂体切除术治疗晚期乳腺癌.中华外科杂志，1960，8：426.
[47]宋三泰.乳腺癌化疗及内分泌治疗的现状及应用策略.中华乳腺病杂志，2003，1(1)：17.
[48]宋三泰.乳腺癌化疗的现状及应该注意的几个问题.中华医学杂志，1997，77(7)：484.
[49]Chia Y H，Ellis M J，Ma C X.Neoadjuvant e nclocrine Lhe rapy in prilllary breast cancer：incli calions ancl use as a research tool.British J Cancer，2010，103(6)，759-764.
[50]Beresford M J，Ravichal1c1ran D，Makris A.Neoadjuvant endocrine therapy in breast cancer.Cancer Treatment Reviews，2007，33(1)：48-57.